Morphine paradoxically prolongs neuropathic pain in rats by amplifying spinal NLRP3 inflammasome activation
Peter M. Grace,Keith A. Strand,Erika L. Galer,Daniel J. Urban,Xiaohui Wang,Michael V. Baratta,Timothy J. Fabisiak,Nathan D. Anderson,Kejun Cheng,Lisa I. Greene,Debra Berkelhammer,Yingning Zhang,Amanda L. Ellis,Hang Hubert Yin,Serge Campeau,Kenner C. Rice,Bryan L. Roth,Steven F. Maier,Linda R. Watkins
DOI: https://doi.org/10.1073/pnas.1602070113
IF: 11.1
2016-05-31
Proceedings of the National Academy of Sciences
Abstract:Significance Pain after disease/damage of the nervous system is predominantly treated with opioids, but without exploration of the long-term consequences. We demonstrate that a short course of morphine after nerve injury doubles the duration of neuropathic pain. Using genetic and pharmacological interventions, and innovative Designer Receptor Exclusively Activated by Designer Drugs disruption of microglia reactivity, we demonstrate that opioid-prolonged neuropathic pain arises from spinal microglia and NOD-like receptor protein 3 inflammasome formation/activation. Inhibiting these processes permanently resets amplified pain to basal levels, an effect not previously reported. These data support the “two-hit hypothesis” of amplification of microglial activation—nerve injury being the first “hit,” morphine the second. The implications of such potent microglial “priming” has fundamental clinical implications for pain and may extend to many chronic neurological disorders.